MATERIALISE NV Business Summary

Materialise NV (MTLS) utilizes a multi-pronged revenue model comprising software licensing, transactional manufacturing services, and medical device sales across three core segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The company derives significant income from its industry-standard Magics and CO-AM software platforms via a mix of SaaS subscriptions and perpetual licenses, while its Medical arm—now its fastest-growing division—generates revenue through personalized implants and clinical planning services. The Manufacturing segment provides high-end rapid prototyping and serial production for aerospace and automotive clients. Positioned as the "backbone" of the industry, Materialise competes with 3D Systems, Stratasys, and Protolabs, yet maintains a unique competitive advantage through its hardware-agnostic software suite that manages heterogeneous machine fleets, unlike its more hardware-centric rivals. Founded in 1990 by Wilfried Vancraen and Hilde Ingelaere, Materialise is currently led by CEO Brigitte de Vet-Courtens, who assumed the role in 2024 after successfully scaling the company’s Medical business and holding prior leadership positions at Johnson & Johnson. The executive leadership includes Chief Strategy and Technology Officer Bart Van der Schueren, a co-founding pioneer in additive manufacturing, and CFO Koen Berges, who oversees global financial operations following a career at ExxonMobil and PwC. The company’s strategic direction is guided by a board chaired by Vancraen and featuring notable directors such as Peter Leys and Jurgen Ingels. Materialise remains a key holding for major institutional investors like ARK Investment Management and Disciplined Growth Investors, reflecting its status as a foundational technology provider in the global 3D printing ecosystem.